A Novel Method Enabling the Use of Small Muscle Samples to Identify Insulin Effects on Akt 2 and AS 160 Subcellular Localization
Deqiang Zhang,Xin Tong,Kyle VanDommelen,Graham F. Brady,Zhuoxian Meng,Jiandie Lin,Liangyou Rui,M. Bishr Omary,Lei Yin
2016-01-01
Abstract:SUBMISSION DEADLINE: OCTOBER 1, 2016 TARGETED AUDIENCE • Clinicians and allied health professionals with an interest in nutrition, obesity, and metabolism • Researchers interested in basic and translational research in nutrition, obesity, and metabolic diseases • Students in health related fields of study OBJECTIVES Symposium participants will enhance their performance, understand and be able to implement in their practice: • The latest basic and clinical supported sciences in treating obesity and metabolic diseases • The role of metabolomics in the pathophysiology of disease • Analyze practice experience and improve practice • Technology in the preclinical assessment of obesity and nutrition-related diseases CME CREDITS This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School and the School of Public Health. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians. The University of Michigan Medical School designates this live activity for a maximum of 6.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Michigan Metabolomics and Obesity Center SYMPOSIUM Focus Topic: Pediatric Obesity Tuesday, October 11, 2016 • 8 a.m. – 4:30 p.m. • Forum Hall, Palmer Commons Disclosure of Relevant Financial Relationships with Commercial Companies The Accreditation Council for Continuing Medical Education (ACCME) requires CME providers to identify and resolve all potential conflicts of interest of planner and presenters prior to a CME activity. “Relevant financial relationships” are those in which an individual (including spouse/domestic partner) has both: (1) a personal financial relationship (any amount) with a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients) in the past 12 months, whether the relationship has no ended or is currently active. (2) control in planning or presenting educational content addressing specific products of the commercial interest (not simply a whole class of products as a group). The following planners/speakers have/had NO relevant personal financial relationships. Karen E. Peterson, DSc Brian Wansink, PhD Katherine W. Bauer, PhD Marie-France Hivert, MD, MMSc Margo Wootan, DSc David Ludwig, MD, PhD The following planners/speakers have/had BOTH (1) a personal financial relationship with a commercial interest and (2) will control educational content about the products of the commercial interest. Charles F. Burant, MD, PhD Metabolic Solutions Development Company (current consultant) Zydus-Cadilla Pharmaceuticals (current consultant) Metabolic Solutions Development Company (current stock shareholder) Darleen Sandoval, PhD Novo Nordisk (current grant/research support) Sanofi (current grant/research support) Boehringer Ingelheim (previous grant/research support) Individual designated to resolve conflict of interest: William Herman, MD, MPH